News >

Rituximab Regimen Elicits High ORR in Relapsed MCL

Danielle Ternyila
Published: Wednesday, Jul 17, 2019

Rory McCulloch, MD, of the Department of Hematology, University Hospital of Plymouth, United Kingdom

Rory McCulloch, MD

Rituximab (Rituxan) in combination with bendamustine and cytarabine (R-BAC) demonstrated an 89.3% overall response rate (ORR) in patients with relapsed/refractory mantle cell lymphoma (MCL) who have previously relapsed on BTK inhibitor, according to retrospective findings presented at the 2019 European Hematology Association Congress. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication